Skip to content

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of ZKY001 Eye Drops

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of ZKY001 Eye Drops in Patients with Corneal Epithelial Defects After TPRK

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06209203
Acronym
TPRK
Enrollment
120
Registered
2024-01-17
Start date
2022-08-03
Completion date
2022-11-08
Last updated
2025-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Epithelium Defect

Brief summary

A multicenter, randomized, double-blind, placebo-controlled clinical trial was designed. A total of 120 subjects were randomly assigned to two experimental groups (lowe-dose ZKY001 eye drops group,Medium-dose ZKY001 eye drops group) and a placebo control group, with 40 subjects in each group.

Detailed description

Study cycle: 7 days screening period (d-7-D-1), 7 days treatment period (D0-D6), and the end of the study on D7. Statistical analysis was performed using SAS9.4 or above software. All statistical tests were two-sided, and P less than or equal to 0.05 was considered statistically significant for the difference being tested unless specified.

Interventions

DRUGplacebo

eye drops

Sponsors

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

1. Age of 18-40 years old, regardless of gender; 2. Plan TPRK for myopia and/or myopic astigmatism, meet the indications for TPRK, and set the ablation diameter of the optical zone at 6.0-6.5 mm; 3. Schirmer test I ≥10mm/5min;

Exclusion criteria

1. prior corneal refractive surgery or keratoplasty; 2. Contraindications to TPRK surgery, including severe ocular surface disease that may affect the corneal epithelium, active ocular inflammation, moderate to severe dry eye, keratoconus or other types of corneal ectasia, thin corneas, severe lesions of ocular appendages (such as eyelid defects, deformations, etc.), glaucoma, cataract that affects vision, History of systemic immune diseases (systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, etc.); 3. incomplete eyelid closure; 4. corneal degeneration, corneal stroma or endothelial damage or malnutrition;

Design outcomes

Primary

MeasureTime frameDescription
healing timeseven daysCorneal epithelial healing time

Secondary

MeasureTime frameDescription
number of healingseven daysThe percentage of corneal healing at 24h, 48h, 72h, 120h and 168h after operation

Other

MeasureTime frameDescription
Corneal stainingseven daysThe percentage of corneal staining negative at 48h, 72h, 120h and 168h after surgery

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026